On October 4, 2022, the Health and Human Services announced their intention on purchasing 290M worth of the drug Nplate (from Amgen USA, Inc). Nplate is approved to treat blood cell injuries that accompany acute radiation syndrome in adults and pediatric patients. Their announcement said the following:
As part of long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies, the U.S. Department of Health and Human Services is purchasing a supply of the drug Nplate from Amgen USA Inc; Nplate is approved to treat blood cell injuries that accompany acute radiation syndrome in adult and pediatric patients (ARS).
They go on to say:
BARDA is using its authority provided under the 2004 Project Bioshield Act and 90 million in Project BioShield designated funding to purchase this supply of the drug. Amgen will maintain this supply in vendor-managed inventory. This approach decreases life-cycle management costs for taxpayers because doses that near expiration can be rotated into the commercial market for rapid use prior to expiry and new doses can be added to the government supply.
The link to their official announcement is below.
The embedded archived version of their announcement is below.